Blau Farmacêutica S.A. (BVMF:BLAU3)
Brazil · Delayed Price · Currency is BRL 9.08
+0.27 (3.06%)
Aug 19, 2026, 5:05 PM GMT-3
Blau Farmacêutica Income Statement
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,786 | 1,702 | 1,754 | 1,373 | 1,407 | 1,366 | |
Revenue Growth | 1.06% | -2.96% | 27.81% | -2.44% | 2.96% | 15.62% |
Cost of Revenue | 1,048 | 1,020 | 1,096 | 882.38 | 739.03 | 700.47 |
Gross Profit | 738.36 | 682.74 | 658.75 | 490.25 | 667.88 | 665.93 |
Selling, General & Admin | 385.37 | 352.99 | 313.77 | 150.28 | 213.85 | 201.77 |
Other Operating Expenses | 44.28 | -24.64 | 16.19 | -117.75 | 1.83 | 5.41 |
Operating Expenses | 429.65 | 328.35 | 329.95 | 41.97 | 215.69 | 209.31 |
Operating Income | 308.71 | 354.39 | 328.8 | 448.28 | 452.19 | 456.62 |
Interest Expense | -94.32 | -71.88 | -58.31 | -32.11 | -32.43 | -26.8 |
Interest & Investment Income | 36.61 | 48.07 | 46.69 | 55.8 | 70.22 | 34.95 |
Earnings From Equity Investments | - | - | - | 0.16 | - | - |
Currency Exchange Gain (Loss) | 11.28 | 21.69 | -18.89 | -8.6 | -4.45 | 1.23 |
Other Non Operating Income (Expenses) | 37.91 | 36.21 | -6.39 | -10.3 | -16.97 | 16.46 |
EBT Excluding Unusual Items | 300.18 | 388.47 | 291.89 | 453.23 | 468.56 | 482.47 |
Other Unusual Items | - | - | - | -119 | - | - |
Pretax Income | 300.18 | 388.47 | 291.89 | 334.23 | 468.56 | 482.47 |
Income Tax Expense | 65.45 | 91.7 | 78.36 | 86.74 | 108.07 | 158.6 |
Earnings From Continuing Operations | 234.73 | 296.77 | 213.53 | 247.49 | 360.49 | 323.86 |
Minority Interest in Earnings | -0.9 | -1.82 | 3.68 | 2.32 | 2.88 | 1.36 |
Net Income | 233.83 | 294.96 | 217.21 | 249.81 | 363.37 | 325.22 |
Net Income to Common | 225.81 | 294.96 | 217.21 | 249.81 | 363.37 | 325.22 |
Net Income Growth | -22.32% | 35.80% | -13.05% | -31.25% | 11.73% | 27.87% |
Shares Outstanding (Basic) | - | 231 | 231 | 231 | 231 | 233 |
Shares Outstanding (Diluted) | - | 231 | 231 | 231 | 231 | 233 |
Shares Change | - | - | - | -0.08% | -0.87% | 13.84% |
EPS (Basic) | - | 1.28 | 0.94 | 1.08 | 1.57 | 1.39 |
EPS (Diluted) | - | 1.28 | 0.94 | 1.08 | 1.57 | 1.39 |
EPS Growth | - | 35.80% | -13.05% | -31.18% | 12.69% | 12.33% |
Free Cash Flow | 221.15 | 28.8 | 364.53 | 71.14 | 29.24 | 5.93 |
Free Cash Flow Per Share | - | 0.13 | 1.58 | 0.31 | 0.13 | 0.03 |
Dividend Per Share | - | - | - | 0.295 | 0.495 | - |
Dividend Growth | - | - | - | -40.40% | - | - |
Gross Margin | 41.34% | 40.11% | 37.55% | 35.72% | 47.47% | 48.74% |
Operating Margin | 17.28% | 20.82% | 18.74% | 32.66% | 32.14% | 33.42% |
Profit Margin | 12.64% | 17.33% | 12.38% | 18.20% | 25.83% | 23.80% |
Free Cash Flow Margin | 12.38% | 1.69% | 20.78% | 5.18% | 2.08% | 0.43% |
EBITDA | 370.7 | 405.37 | 368.91 | 478.15 | 469.62 | 474.85 |
EBITDA Margin | 20.76% | 23.81% | 21.03% | 34.83% | 33.38% | 34.75% |
D&A For EBITDA | 61.99 | 50.98 | 40.11 | 29.87 | 17.43 | 18.22 |
EBIT | 308.71 | 354.39 | 328.8 | 448.28 | 452.19 | 456.62 |
EBIT Margin | 17.28% | 20.82% | 18.74% | 32.66% | 32.14% | 33.42% |
Effective Tax Rate | 21.80% | 23.61% | 26.85% | 25.95% | 23.06% | 32.87% |